EUVIMEDEUVIMED entdecken
Crossref

A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy

Sowmya MS, Manjunath Manjunath, Basavanna PL, Ramya KN, Mukesh Mukesh

Journal of Clinical Research and Applied Medicine · 2022

DOI: 10.5530/jcram.1.2.14 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Research and Applied Medicine, 2022. Verfasst von Sowmya MS und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

MS, S., Manjunath, M., PL, B., KN, R., & Mukesh, M. (2022). A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy. Journal of Clinical Research and Applied Medicine. https://doi.org/10.5530/jcram.1.2.14

Vancouver

MS S, Manjunath M, PL B, KN R, Mukesh M. A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy. Journal of Clinical Research and Applied Medicine. 2022. doi:10.5530/jcram.1.2.14

BibTeX
@article{MS2022,
  author = {MS, Sowmya and Manjunath, Manjunath and PL, Basavanna and KN, Ramya and Mukesh, Mukesh},
  title = {A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy},
  journal = {Journal of Clinical Research and Applied Medicine},
  year = {2022},
  doi = {10.5530/jcram.1.2.14}
}
Kostenlos starten →